Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow (2024 - 2025)

Silence Therapeutics' Net Cash Flow history spans 2 years, with the latest figure at -$70.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 283.18% year-over-year to -$70.6 million; the TTM value through Dec 2025 reached -$110.2 million, down 310.07%, while the annual FY2025 figure was -$110.2 million, 310.07% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$70.6 million at Silence Therapeutics, down from $40.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $74.0 million in Q1 2024 and bottomed at -$70.6 million in Q4 2025.